These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32282852)

  • 1. Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data.
    Gabriel R; Boukichou Abdelkader N; Acosta T; Gilis-Januszewska A; Gómez-Huelgas R; Makrilakis K; Kamenov Z; Paulweber B; Satman I; Djordjevic P; Alkandari A; Mitrakou A; Lalic N; Colagiuri S; Lindström J; Egido J; Natali A; Pastor JC; Teuschl Y; Lind M; Silva L; López-Ridaura R; Tuomilehto J;
    PLoS One; 2020; 15(4):e0231196. PubMed ID: 32282852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of linagliptin on endothelial function and global arginine bioavailability ratio in coronary artery disease patients with early diabetes: study protocol for a randomized controlled trial.
    Tripolt NJ; Aberer F; Riedl R; Hutz B; Url J; Dimsity G; Meinitzer A; Stojakovic T; Hödl R; Brodmann M; Hafner F; Sourij H
    Trials; 2016 Oct; 17(1):495. PubMed ID: 27733180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.
    Groop PH; Cooper ME; Perkovic V; Hocher B; Kanasaki K; Haneda M; Schernthaner G; Sharma K; Stanton RC; Toto R; Cescutti J; Gordat M; Meinicke T; Koitka-Weber A; Thiemann S; von Eynatten M
    Diabetes Obes Metab; 2017 Nov; 19(11):1610-1619. PubMed ID: 28636754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial.
    Guardado-Mendoza R; Salazar-López SS; Álvarez-Canales M; Farfán-Vázquez D; Martínez-López YE; Jiménez-Ceja LM; Suárez-Pérez EL; Angulo-Romero F; Evia-Viscarra ML; Montes de Oca-Loyola ML; Durán-Pérez EG; Folli F; Aguilar-García A
    Metabolism; 2020 Mar; 104():154054. PubMed ID: 31887309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
    Diabetes Prevention Program Research Group
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):866-75. PubMed ID: 26377054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study.
    Gong Q; Gregg EW; Wang J; An Y; Zhang P; Yang W; Li H; Li H; Jiang Y; Shuai Y; Zhang B; Zhang J; Gerzoff RB; Roglic G; Hu Y; Li G; Bennett PH
    Diabetologia; 2011 Feb; 54(2):300-7. PubMed ID: 21046360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
    Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle.
    Alvarez-Canales MFL; Salazar-López SS; Farfán-Vázquez D; Martínez-López YE; González-Mena JN; Jiménez-Ceja LM; Vargas-Ortiz K; Evia-Viscarra ML; Montes de Oca-Loyola ML; Folli F; Aguilar-García A; Guardado-Mendoza R
    Sci Rep; 2021 Apr; 11(1):8750. PubMed ID: 33888772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin.
    Katsuda Y; Sasase T; Tadaki H; Mera Y; Motohashi Y; Kemmochi Y; Toyoda K; Kakimoto K; Kume S; Ohta T
    Exp Anim; 2015; 64(2):161-9. PubMed ID: 25736710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
    Ismail-Beigi F; Craven T; Banerji MA; Basile J; Calles J; Cohen RM; Cuddihy R; Cushman WC; Genuth S; Grimm RH; Hamilton BP; Hoogwerf B; Karl D; Katz L; Krikorian A; O'Connor P; Pop-Busui R; Schubart U; Simmons D; Taylor H; Thomas A; Weiss D; Hramiak I;
    Lancet; 2010 Aug; 376(9739):419-30. PubMed ID: 20594588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
    Biessels GJ; Janssen J; van den Berg E; Zinman B; Espeland MA; Mattheus M; Johansen OE;
    BMC Neurol; 2018 Jan; 18(1):7. PubMed ID: 29334906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study Protocol: The Norfolk Diabetes Prevention Study [NDPS]: a 46 month multi - centre, randomised, controlled parallel group trial of a lifestyle intervention [with or without additional support from lay lifestyle mentors with Type 2 diabetes] to prevent transition to Type 2 diabetes in high risk groups with non - diabetic hyperglycaemia, or impaired fasting glucose.
    Pascale M; Murray N; Bachmann M; Barton G; Clark A; Howe A; Greaves C; Sampson M
    BMC Public Health; 2017 Jan; 17(1):31. PubMed ID: 28056894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial.
    Feig DS; Murphy K; Asztalos E; Tomlinson G; Sanchez J; Zinman B; Ohlsson A; Ryan EA; Fantus IG; Armson AB; Lipscombe LL; Barrett JF;
    BMC Pregnancy Childbirth; 2016 Jul; 16(1):173. PubMed ID: 27435163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
    Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.
    Gæde P; Oellgaard J; Carstensen B; Rossing P; Lund-Andersen H; Parving HH; Pedersen O
    Diabetologia; 2016 Nov; 59(11):2298-2307. PubMed ID: 27531506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
    Zeng Z; Yang JK; Tong N; Yan S; Zhang X; Gong Y; Woerle HJ
    Curr Med Res Opin; 2013 Aug; 29(8):921-9. PubMed ID: 23672632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.
    Ohkubo Y; Kishikawa H; Araki E; Miyata T; Isami S; Motoyoshi S; Kojima Y; Furuyoshi N; Shichiri M
    Diabetes Res Clin Pract; 1995 May; 28(2):103-17. PubMed ID: 7587918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).
    Freedman BI; Wuerth JP; Cartwright K; Bain RP; Dippe S; Hershon K; Mooradian AD; Spinowitz BS
    Control Clin Trials; 1999 Oct; 20(5):493-510. PubMed ID: 10503809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study.
    O'Brien R; Johnson E; Haneuse S; Coleman KJ; O'Connor PJ; Fisher DP; Sidney S; Bogart A; Theis MK; Anau J; Schroeder EB; Arterburn D
    Ann Intern Med; 2018 Sep; 169(5):300-310. PubMed ID: 30083761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.